Rate and predictors of loss to follow-up in HIV care in a low-resource setting: analyzing critical risk periods
Published in Biomedical Research
Why Do Some People Stop HIV Treatment? Understanding the Key Moments
In the global fight against HIV, keeping people engaged in their treatment is crucial. Even though many countries aim to meet ambitious HIV care goals by 2030, a significant challenge remains: helping those who start HIV treatment continue their care and keep their virus under control. A big part of this challenge is what’s known as "loss to follow-up" (LTFU).
What is Loss to Follow-Up (LTFU)?
LTFU happens when someone on HIV treatment misses their medical appointments or stops taking their medication for over 28 days. This is a serious issue, as it can lead to poorer health, increased risk of death, and a higher chance of spreading HIV to others because the virus isn’t being suppressed.
When Do People Stop Treatment?
This study looked at 737 adults who were new to HIV care and identified the times when they were most likely to stop their treatment:
- The First 6 Months Are Critical: About 50% of the people who dropped out of care did so within the first six months. This early period is a high-risk time, with an LTFU rate nine times higher than later periods (13-24 months). People might face challenges like dealing with side effects, struggling to adjust to a new routine, or not yet seeing the benefits of the medication.
- 7-12 Months: A Continued Risk: Even though the risk of dropping out decreases after the first six months, many people still struggle to stick with their treatment during months 7-12. About 30% of those who stopped care did so during this time. Factors like financial difficulties, stigma, or transportation issues can continue to affect them.
- After 12 Months: A More Stable Phase: After a year on treatment, the dropout rate drops significantly. By this time, many patients have adjusted to their routine, seen improvements in their health, and are more committed to their treatment.
What Can We Do About It?
The findings suggest that the first six months of HIV treatment are a make-or-break time. Health programs should focus on providing extra support during this period, such as helping patients manage side effects and offering counseling. Continued support is also important in the following months to help people overcome challenges that might come up later.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Infectious diseases in pregnancy
BMC Infectious Diseases invites submissions for a Collection on Infectious diseases in pregnancy.
Infectious diseases during pregnancy represent a critical area of concern for maternal and fetal health. Infections such as syphilis, HIV, and Zika virus can have severe implications for both the mother and the developing fetus, leading to complications such as congenital infections, vertical transmission, and adverse pregnancy outcomes. Understanding the mechanisms of maternal infections and their potential impacts on fetal development is vital for optimizing prenatal care and improving health outcomes. This Collection seeks to explore the latest research in this field, focusing on the complexities and challenges associated with infectious disease management in pregnancy.
Addressing infectious diseases in pregnancy is essential not only for safeguarding maternal health but also for preventing long-term effects on child health and development. Advances in prenatal screening and diagnostic techniques have improved our ability to detect and manage infections, enabling timely interventions that can significantly reduce risks. Furthermore, increased awareness and research into gestational infections have led to better guidelines for healthcare providers, fostering a more proactive approach to managing maternal-fetal health during pregnancy. Continued research in this field could lead to further advancements in treatment and prevention, including vaccines, biomarkers, and screening.
We invite clinicians and researchers in infectious disease management, obstetrics, public health, immunology, epidemiology, maternal-fetal medicine, and related fields to contribute original research articles on topics including but not limited to:
- Maternal infections and fetal outcomes
- Congenital infections and their management
- Vertical transmission of infectious agents
- Advances in prenatal screening techniques
- Perinatal infections: risks and interventions
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 30, 2026
Hepatitis virus infections and treatment
BMC Infectious Diseases invites submissions for a Collection on Hepatitis virus infections and treatment.
Hepatitis virus infections—including types A, B, C, D, and E—remain a significant global public health concern, collectively affecting hundreds of millions of people and contributing to a wide spectrum of liver-related diseases. These range from acute hepatitis and chronic liver inflammation to cirrhosis and hepatocellular carcinoma. Each hepatitis virus presents unique challenges in terms of transmission, disease progression, and treatment, with varying impacts across different regions and populations.
While hepatitis C has seen transformative progress with the development of Direct-Acting Antivirals (DAAs), hepatitis B continues to pose challenges due to its chronic nature and the need for lifelong management. Hepatitis A and E, typically transmitted via the fecal-oral route, are preventable through improved sanitation and vaccination, yet outbreaks still occur in resource-limited settings. Hepatitis D, which only occurs in conjunction with hepatitis B, adds complexity to diagnosis and treatment strategies.
Recent advances in diagnostics, therapeutics, and public health interventions have improved outcomes for many affected individuals. However, disparities in access to care, limited awareness, and gaps in screening and vaccination programs hinder global efforts to eliminate viral hepatitis as a public health threat. Continued research is essential to develop more effective prevention strategies, enhance treatment protocols, and understand the epidemiological and clinical nuances of each hepatitis virus. This Collection welcomes research that explores:
- Innovations in antiviral therapies across hepatitis types
- Epidemiology and transmission dynamics of hepatitis A–E
- Vaccine development and implementation strategies
- Novel diagnostic tools for acute and chronic hepatitis
- Public health approaches to hepatitis prevention and control
- Clinical implications of co-infections (e.g., HBV/HDV)
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 20, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in